COVID-19 and psychiatric disorders among young people: a cross-sectional study.

IF 2.1 3区医学 Q3 PHARMACOLOGY & PHARMACY International Clinical Psychopharmacology Pub Date : 2024-08-22 DOI:10.1097/YIC.0000000000000565

Tiziano Prodi, Filippo Dragogna, Beatrice Benatti, Alberto Varinelli, Simone Vanzetto, Letizia Gianfelice, Bernardo Dell'Osso

{"title":"COVID-19 and psychiatric disorders among young people: a cross-sectional study.","authors":"Tiziano Prodi, Filippo Dragogna, Beatrice Benatti, Alberto Varinelli, Simone Vanzetto, Letizia Gianfelice, Bernardo Dell'Osso","doi":"10.1097/YIC.0000000000000565","DOIUrl":null,"url":null,"abstract":"<p><p>During the COVID-19 pandemic, a significant rise in mental health issues was observed. Particularly, children and adolescents have shown a higher risk of developing mental disorders than adults. This study aimed to describe the evolving features of the requests for psychiatric emergency interventions during the COVID-19 pandemic in young people. We conducted a cross-sectional study comparing the number, characteristics, and symptoms of people aged between 12 and 18 years old attending one Emergency Department (ED) for psychiatric issues, considering three different periods: T0 (8 March 2019-7 March 2020), T1 (8 March 2020-7 March 2021), and T2 (8 March 2021-7 March 2022). Total admissions were 220: 99 (45%) during T0, 40 (18.1%) for T1, and 81 (36.8%) for T2 ( P < 0.001). A significant decrease in the mean age from T0 to T1 was found ( P < 0.01). Admissions for psychomotor agitation decreased, while admission due to anxiety disorder and nonsuicidal self-injury raised significantly ( P < 0.05), as for first psychiatric presentation ( P < 0.01). Regarding substance use, a significant reduction was observed ( P < 0.05). The rates of eating disorders ( P < 0.001) and early insomnia ( P < 0.01) increased from T0. These findings highlight the worsening of psychiatric symptoms in the young population during the COVID-19 pandemic.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/YIC.0000000000000565","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

During the COVID-19 pandemic, a significant rise in mental health issues was observed. Particularly, children and adolescents have shown a higher risk of developing mental disorders than adults. This study aimed to describe the evolving features of the requests for psychiatric emergency interventions during the COVID-19 pandemic in young people. We conducted a cross-sectional study comparing the number, characteristics, and symptoms of people aged between 12 and 18 years old attending one Emergency Department (ED) for psychiatric issues, considering three different periods: T0 (8 March 2019-7 March 2020), T1 (8 March 2020-7 March 2021), and T2 (8 March 2021-7 March 2022). Total admissions were 220: 99 (45%) during T0, 40 (18.1%) for T1, and 81 (36.8%) for T2 ( P < 0.001). A significant decrease in the mean age from T0 to T1 was found ( P < 0.01). Admissions for psychomotor agitation decreased, while admission due to anxiety disorder and nonsuicidal self-injury raised significantly ( P < 0.05), as for first psychiatric presentation ( P < 0.01). Regarding substance use, a significant reduction was observed ( P < 0.05). The rates of eating disorders ( P < 0.001) and early insomnia ( P < 0.01) increased from T0. These findings highlight the worsening of psychiatric symptoms in the young population during the COVID-19 pandemic.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

COVID-19 与青少年精神障碍：一项横断面研究。

在 COVID-19 大流行期间，心理健康问题显著增加。尤其是儿童和青少年比成年人患精神疾病的风险更高。本研究旨在描述 COVID-19 大流行期间青少年要求精神科紧急干预的演变特征。我们进行了一项横断面研究，比较了因精神问题到一家急诊科（ED）就诊的 12 至 18 岁人群的数量、特征和症状，并考虑了三个不同时期：T0（2019 年 3 月 8 日至 2020 年 3 月 7 日）、T1（2020 年 3 月 8 日至 2021 年 3 月 7 日）和 T2（2021 年 3 月 8 日至 2022 年 3 月 7 日）。入院总人数为 220 人：T0 期为 99 人（45%），T1 期为 40 人（18.1%），T2 期为 81 人（36.8%）（P < 0.001）。从 T0 到 T1，平均年龄明显下降（P < 0.01）。因精神运动性躁动入院的人数有所减少，而因焦虑症和非自杀性自伤入院的人数显著增加（P < 0.05），首次出现精神病症状的人数也显著增加（P < 0.01）。在药物使用方面，也观察到了明显的减少（P < 0.05）。饮食失调（P < 0.001）和早期失眠（P < 0.01）的发病率比 T0 有所上升。这些研究结果突显出，在 COVID-19 大流行期间，年轻人的精神症状有所恶化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Clinical Psychopharmacology 医学-精神病学

CiteScore

4.40

自引率

23.10%

发文量

审稿时长

>12 weeks

期刊介绍： International Clinical Psychopharmacology provides an essential link between research and clinical practice throughout psychopharmacology. It reports on studies in human subjects, both healthy volunteers and patients, which relate the effects of drugs on psychological processes. A major objective of the journal is to publish fully refereed papers which throw light on the ways in which the study of psychotropic drugs can increase our understanding of psychopharmacology. To this end the journal publishes results of early Phase I and II studies, as well as those of controlled clinical trials of psychotropic drugs in Phase II and IV. Other topics covered include the epidemiology of psychotropic drug prescribing and drug taking, the sociology of psychotropic drugs including compliance, and research into the safety and adverse effects of these compounds.